IRVINE, Calif. and
TEMPLE CITY, Calif., Nov. 1, 2021 /PRNewswire/ -- Helio
Health ("Helio"), an AI-driven healthcare company developing
blood-based early cancer detection tests, and Fulgent Genetics,
Inc. (NASDAQ: FLGT) ("Fulgent"), a technology-based genetic testing
company focused on transforming patient care in oncology,
infectious and rare diseases, and reproductive health, today
announced its upcoming late-breaking poster presentation on the
performance of HelioLiver, a multi-analyte blood test that
utilizes both cell-free DNA (cfDNA) methylation patterns and
protein tumor markers for the detection of hepatocellular carcinoma
(HCC), at The Liver Meeting® 2021. The annual meeting is hosted by
the American Association for the Study of Liver Diseases (AASLD)
and will be held virtually November 12-15,
2021.
Details of the poster presentation are as follows:
Poster Title: A Multi-Analyte Blood Test for
Accurate and Early Detection of Hepatocellular Carcinoma
Publication Number: LP44
Session Title: Late-breaking Abstract Posters
Presenter: David J. Taggart,
PhD, NRCC(CC) – Laboratory Director and Vice President of
Laboratory Operations and Regulatory Affairs, Helio Health
Inc.
The full abstract can be found here. The poster presentation
will be available for viewing by the attendees of The Liver
Meeting® throughout the entire meeting.
About Helio Health
Helio Health is an AI-driven healthcare company focused on
commercializing early cancer detection tests from a simple blood
draw. The company's mission is to simplify cancer screening so
lives can be saved by detecting cancer earlier. With Helio's
AI-driven technology, both physicians and their patients gain
powerful insights from accurate, accessible, and convenient blood
tests.
Building on a robust research and development program, and with
access to thousands of patient samples, the company is currently in
clinical trials in the US and China with its lead liver cancer detection
test. Helio's development program is focused on liver, colon,
breast and lung cancer.
Helio Health is headquartered in Irvine, CA, with R&D, GMP and CLIA
facilities in Irvine, CA and
West Lafayette, IN, Guangzhou and Beijing.
About Fulgent Genetics
Fulgent Genetics is a technology-based genetic testing company
focused on transforming patient care in oncology, infectious and
rare diseases, and reproductive health. Fulgent's proprietary
technology platform has created a broad, flexible test menu and the
ability to continually expand and improve its proprietary genetic
reference library while maintaining accessible pricing, high
accuracy, and competitive turnaround times. Combining next
generation sequencing with its technology platform, Fulgent
performs full-gene sequencing with deletion/duplication analysis in
an array of panels that can be tailored to meet specific customer
needs. A cornerstone of our business is our ability to provide
expansive options and flexibility for all clients' unique testing
needs through a comprehensive technology offering including cloud
computing, pipeline services, record management, web portal
services, clinical workflow, sequencing as a service and automated
lab services.
About Helio Health and Fulgent Genetics Partnership
In a strategic partnership announced in August of 2021, Helio
Health and Fulgent Genetics plan to commercialize and co-brand
HelioLiver, a cell-free DNA (cfDNA) methylation blood test that
incorporates protein markers and demographics for the detection of
hepatocellular carcinoma (HCC) – or liver cancer. HelioLiver is
currently undergoing clinical trials in the U.S. and China. Fulgent will be responsible for
laboratory operations, supply chain operations, and marketing and
sales leveraging its operational excellence and significant market
reach, initially focused in the U.S. and Canada. Helio will provide intellectual
property and continued support across research and development,
publication development, market access and sales, as well as
reimbursement operations. Fulgent and Helio will also collaborate
on the development of additional liquid biopsy tests for different
types of cancer in the future.
![Fulgent Genetics, Inc. Logo Fulgent Genetics, Inc. Logo](https://mma.prnewswire.com/media/1675734/Fulgent_Genetics_Logo.jpg)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/helio-health-and-fulgent-genetics-to-present-new-data-on-helioliver-in-late-breaking-presentation-at-the-liver-meeting-2021-301413267.html
SOURCE Helio Health and Fulgent Genetics, Inc.